| abstract |
The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells. |